



(51) International Patent Classification:

C07D 487/14 (2006.01) *A61P 25/00* (2006.01)
A61K 31/519 (2006.01) *A61P 9/00* (2006.01)

(21) International Application Number:

PCT/US2013/046415

(22) International Filing Date:

18 June 2013 (18.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/661,091 18 June 2012 (18.06.2012) US

(71) Applicant: **DART NEUROSCIENCE (CAYMAN) LTD**;
4th Floor, Queensgate House, 113 South Church Street,
P.O. Box 1994, Grand Cayman, KY1 1104 (KY).(72) Inventors: **ALLAN, Amy**; 542 San Dieguito Drive, Encin-
itas, CA 92024 (US). **BRANSTETTER, Bryan**; 4747
Marina Dr. #3, Carlsbad, CA 92008 (US). **DYCK, Brian**;
9242 Pebblestone Lane, San Diego, CA 92126 (US).
WEINHOUSE, Michael, I.; 3215 Purer Rd., Escondido,
CA 92029 (US). **GOMEZ, Laurent**; 13270 Russet Leaf

Lane, San Diego, CA 92129 (US). **MARRONE, Tammi. Jo**; 6420 Ruby Way, Carlsbad, CA 92011 (US). **PETERS, Marco**; 4567 Louisiana Street, San Diego, CA 92116 (US).

(74) Agent: **MILLER, Kimberly, J.**; Knobbe Martens Olson
& Bear LLP, 2040 Main Street, 14th Floor, Irvine, CA
92614 (US).(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: SUBSTITUTED PYRIDINE AZOLOPYRIMIDINE - 5 - (6H) - ONE COMPOUNDS




FIG. 1

(57) Abstract: Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders



EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*